Context Therapeutics Reports Positive Phase 1 CTIM-76 Data in Ovarian Cancer
CNTX has more than doubled off its 52-week low of $0.56.
Summary
Context Therapeutics announced positive interim Phase 1 clinical trial results for its lead cancer drug candidate, CTIM-76, showing a 29% overall response rate and a favorable safety profile in heavily pre-treated ovarian cancer patients.
Key Events · Product Development and Regulatory · CNTX
-
Positive Phase 1 CTIM-76 Results
Context Therapeutics announced positive interim efficacy and safety results from its ongoing Phase 1 clinical trial for CTIM-76, its lead Claudin 6 x CD3 T cell engaging bispecific antibody.
-
Significant Overall Response Rate (ORR)
The trial achieved a 29% confirmed overall response rate (ORR) per RECIST v1.1 in patients with platinum-resistant ovarian cancer (PROC) who had progressed on a median of 7 prior lines of therapy.
-
Favorable Safety Profile
The safety profile was well-tolerated, with Cytokine Release Syndrome (CRS) limited to Grade 1 in only 11% of PROC patients at active dose levels, supporting potential outpatient dosing.
-
Optimized Dosing Schedule
Pharmacokinetic (PK) data supports the exploration of a less frequent, every three weeks (Q3W), dosing schedule in the second half of 2026, potentially enhancing treatment durability and convenience.
Analysis · CNTX · Life Sciences
This filing reports significant positive interim Phase 1 clinical data for Context Therapeutics' lead bispecific antibody, CTIM-76, in platinum-resistant ovarian cancer. The 29% overall response rate in heavily pre-treated patients, combined with a favorable safety profile and low incidence of severe cytokine release syndrome, is a critical de-risking event for the program. This positive clinical update, along with the confirmed cash runway into mid-2027, is crucial for the company's valuation and future financing efforts, especially following recent reports of increased cash burn.
At the time of this filing, CNTX was trading at $1.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $127.7M. The 52-week trading range was $0.56 to $3.62. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.